American Bio Medica
OTCMKTS:ABMCAmerican Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
Phio Pharmaceuticals
NASDAQ:PHIOPhio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Regulus Therapeutics
NASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Salarius Pharmaceuticals
NASDAQ:SLRXSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Tetraphase Pharmaceuticals
NASDAQ:TTPHTetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.